Fluorescence-Quenching Substrate for ADAMTS-13
(aka von Willebrand factor (vWF) cleaving protease)
Now Available from Peptides International


Thrombotic thrombocytopenic purpura (TTP) is a rare and potentially fatal blood condition characterized by the formation of microvascular thrombi.  Until recently the cause of TTP remained elusive.   Latest research points to the involvement of a protein in the plasma called von Willebrand factor (vWF). vWF is an extremely large molecule that is able to bind to platelets or to injured blood vessel lining and is a normal component of plasma that is required for blood clotting.  vWF molecules are rather sticky and are usually found circulating in the blood. Normally, they are broken down to slightly smaller sizes so that vWF retains its adhesive properties without binding inappropriately, leading to undesired blood clots.  von Willebrand disease is an inherited condition characterized by excessive bleeding and is due to lack of vWF. In TTP, vWF is synthesised normally but its cleavage is defective. This is considered to be due to the lack of enzyme activity called vWF cleaving protease. The vWF cleaving protease has been reported to be a new member of the ADAMTS family of metalloproteases, designated as ADAMTS-13.

Currently, there is no specific test to confirm the diagnosis of this potentially fatal condition.  A new fluorescent-quenching substrate is now available from the Peptide Institute and Peptides International. This ADAMTS-13 specific substrate should be a valuable tool to aid in the discovery of diagnostic markers for TTP.

1) K. Kokame, M. Matsumoto, Y. Fujimura, and T. Miyata, Blood, 103, 607 (2004). (VWF73 Sequence)
2) K. Kokame, Y. Nobe, Y. Kokubo, A. Okayama, and T. Miyata, Br. J. Haematol., 129, 93 (2005). (FRETS-VWF73)
 
 

Manufactured by the Peptide Institute and Now Available from Peptides International
 

For additional instructions, please refer to the following assay method link:
Assay Method Instructions for Measuring Plasma ADAMTS-13 Activity SFR-3224-s Lot 540911
SFR-3224-s Lot 550116
 

CODE

PRODUCT

QTY

USD

SFR-3224-s
 

 FRETS-VWF73
(Trifluoroacetate Form)
Asp-Arg-Glu-A2pr(Nma)-Ala-Pro-Asn- Leu-Val-Tyr-Met-Val-Thr-Gly-A2pr(Dnp)- Pro-Ala-Ser-Asp-Glu-Ile-Lys-Arg-Leu- Pro-Gly-Asp-Ile-Gln-Val-Val-Pro-Ile-Gly- Val-Gly-Pro-Asn-Ala-Asn-Val-Gln-Glu- Leu-Glu-Arg-Ile-Gly-Trp-Pro-Asn-Ala- Pro-Ile-Leu-Ile-Gln-Asp-Phe-Glu-Thr- Leu-Pro-Arg-Glu-Ala-Pro-Asp-Leu-Val-Leu-Gln-Arg
A2pr(Nma): Nbeta-[2-(Methylamino)benzoyl]-2,3-
diaminopropionic acid
A2pr(Dnp): Nbeta-[2,4-Dinitrophenyl-2,3-
diaminopropionic acid]

(M.W. 8314.3) C370H583N103O113S
Fluorescence-Quenching Substrate
for ADAMTS-13

1) K. Kokame, M. Matsumoto, Y. Fujimura, and T. Miyata, Blood, 103, 607 (2004). (VWF73 Sequence)
2) K. Kokame, Y. Nobe, Y. Kokubo, A. Okayama, and T. Miyata, Br. J. Haematol., 129, 93 (2005). (FRETS-VWF73)

• This compound is produced by Peptide Institute, Inc. under license of the National Cardiovascular Center in Japan. Japanese patent No. 3944586, US patent application No: US-2007-0065895-A1. 

0.1 mg vial

312
space

Please contact our technical specialists for additional inquiries.

Please contact Peptides International for ordering information.
Peptides International, Inc.
PO Box 24658
Louisville, Kentucky 40224 USA
Phone: 502-266-8787 or 800-777-4779
Fax: 502-267-1FAX (1329)
Email:  peptides@pepnet.com

HOME  | Back to New Peptide Institute Products |  E-mail

Search Main Menu Email

Peptides International